Use of Peptides That Block Metadherin-SND1 Interaction as Treatment for Cancer
AssigneesThe Trustees of Princeton University, Wisconsin Alumni Research Foundation
InventorsYibin Kang, Yongna Xing, Liling Wan, Feng Guo
Life of this patent
Estimating the term…
Abstract
The present disclosure related in general to methods of treating cancer by interfering with the interaction of metadherin with Staphylococcal nuclease domain-containing 1 (SND1) using peptides or other compounds that inhibit the binding of SND1 with metadherin and inhibit the activity of the MTDH-SND1 complex in tumor cells.
Claims23
A method for reducing the progression of tumor growth or inhibiting metastasis in a subject having cancer comprising administering to the subject a pharmaceutical composition according to claim 12.
A method of treating cancer in a subject having cancer comprising administering to the subject a pharmaceutical composition according to claim 12.
3-7. (canceled)
10-11. (canceled)
A pharmaceutical composition comprising an inhibitor that disrupts the interaction between metadherin (MTDH) and Staphylococcal nuclease domain containing 1 (SND1) and a pharmaceutically acceptable carrier, excipient or diluent, wherein the inhibitor is a peptide or a fusion protein comprising the peptide linked to one or more polypeptides not generally recognized to be part of the sequence of MTDH, wherein the peptide comprises the amino acid sequence of DWNAPAEEWGN (SEQ ID NO:
- 5) or a variant thereof, wherein the variant has one or two mutations at positions selected from the group consisting of D393, N395, A396, PAE397-399, E399, E400, and N403, wherein the amino acid positions are based on SEQ ID NO:
- 1, and wherein the peptide is about 11 to about 22 amino acids long.
(canceled)
Dependencies are inferred from the claim text.